Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icatibant for Propofol Injection Pain
2025-521354-42-00Phase 2Authorised
- Sponsor
- Oslo University Hospital
- Start
- Aug 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of icatibant (2 arms), sponsored by Oslo University Hospital. Primary endpoint: Area under the curve of Visual Analog Scale pain ≥ 30 mm (0–100 mm) - AUCVAS≥30. Planned start Aug 2025; status: authorised.
02
Drugs
icatibant
Beyond the preview
Go deeper on 2025-521354-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521354-42-00.